{
    "clinical_study": {
        "@rank": "74035", 
        "acronym": "OPUS", 
        "arm_group": {
            "arm_group_label": "Opsumit (macitentan)", 
            "description": "10 mg tablets"
        }, 
        "brief_summary": {
            "textblock": "Prospective observational drug registry developed to characterize the safety profile\n      (including primarily potential serious hepatic risks) and to describe clinical\n      characteristics and outcomes of patients newly treated with Opsumit in the post-marketing\n      setting."
        }, 
        "brief_title": "OPsumit USers Registry", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Arterial Hypertension", 
            "PAH"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients newly treated with Opsumit defined as a new user of therapy, initiated \u2264 30 days\n        prior to enrollment visit.\n\n        Signed ICF\n\n        Exclusion Criteria:\n\n        Previous user of Opsumit defined as patient who initiated therapy >30 days prior to\n        enrollment.\n\n        Patients enrolled in any ongoing clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients newly treated with Opsumit"
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126943", 
            "org_study_id": "AC-055-503"
        }, 
        "intervention": {
            "arm_group_label": "Opsumit (macitentan)", 
            "description": "10 mg tablets", 
            "intervention_name": "Opsumit (macitentan)", 
            "intervention_type": "Drug", 
            "other_name": "ACT-064992"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pulmonary arterial hypertension", 
            "PAH"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "medinfo@actelion.com", 
                "last_name": "Global Medical Information"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45219"
                }, 
                "name": "Investigator Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "US-based, Observational, Drug Registry of Opsumit\u00ae (Macitentan) New Users in Clinical Practice", 
        "other_outcome": {
            "measure": "To describe PAH treatment patterns at enrollment and during observation period.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "medinfo@actelion.com", 
            "last_name": "Daniel Rosenberg"
        }, 
        "overall_official": {
            "affiliation": "Chair of the OPUS scientific committee (OSC)", 
            "last_name": "V McLaughlin, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Liver test abnormalities/ Occurrence of Hepatic Adverse Events (HAEs)/ Occurrence of any other AEs/ Discontinuation of Opsumit and reason for stopping therapy/ Hospitalization and death.", 
            "measure": "To estimate incidence rates for specified outcomes.", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To describe demographic and clinical characteristics of patients treated with Opsumit at enrollment and during observation period.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Actelion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Actelion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}